- Efficacy and safety of selpercatinib in Chinese patients with advanced RET-altered thyroid cancers: results from the phase II LIBRETTO-321 studyZheng, Xiangqian; Ji, Qinghai; Sun, Yuping; Ge, Minghua; Zhang, Bin; Cheng, Ying; Lei, Shangtong; Shi, Feng; Guo, Ye; Li, Linfa; Chen, Lu; Shao, Jingxin; Zhang, Wanli; Gao, Ming*Therapeutic Advances in Medical Oncology, 2022, 14: 17588359221119318.被引 7
- A phase I study of KL590586, a next-generation selective RET inhibitor, in patients with RET-altered solid tumorsZhou, Qing; Wu, Yi-Long; Zheng, Xiangqian; Li, Dapeng; Huang, Dingzhi; Li, Xingya; Liu, Anwen; Song, Xia; Jing, Shanghua; Wang, Mingxia; Wang, Xicheng; Luo, Yongzhong; Song, Yong; Mi, Yanjun; Zhou, Jianying; Fan, Yun; Su, Haichuan; Huang, Tao; Ouyang, Weiwei; Ge, JunyouAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
- Updated analysis of entrectinib in a subset of Chinese (mainland China, Hong Kong, Taiwan) patients (pts) with NTRK fusion-positive (fp) solid tumours and ROS1-fp nonsmall cell lung cancer (NSCLC)Lu, S.; Fan, Y.; Chiu, C-H.; Yu, Y.; Loong, H. H. F.; Lin, C-C.; Dong, X.; Li, J.; Zhao, J.; Zhang, Z.; Zhao, N.; Xu, T.; Hou, M.; Wang, D.; Hu, X.ESMO Asia Congress, Singapore, SINGAPORE, 2022-12-02 To 2022-12-04.
会议论文
LIBRETTO-321, a phase II study of the efficacy and safety of selpercatinib in Chinese patients with advanced RET-altered thyroid cancer (TC)
1被引5阅读
